Cellectis (CLLS)

• Market cap: $368M
• 1 day: 4.57%
• 5 days: -2.66%
• 1 month: -8.73%
• 3 months: -8.96%
• 6 months: -27.38%
• Year to date: -23.75%
• 1 year: 150.68%
• 5 years: -77.3%
• 10 years: -88.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229